Short term recombinant human Growth Hormone administration increases strength and power, but does it improve sporting performance in anabolic-androgenic steroid users?
| ISRCTN | ISRCTN13681882 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN13681882 |
| Secondary identifying numbers | 280361999 |
- Submission date
- 19/10/2006
- Registration date
- 27/10/2006
- Last edited
- 29/06/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Michael Graham
Scientific
Scientific
1 Lantwit Road
Treforrest
Cardiff
CF37 1DL
United Kingdom
Study information
| Study design | Double blind experimental trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Quality of life |
| Scientific title | Short term recombinant human Growth Hormone administration increases strength and power, but does it improve sporting performance in anabolic-androgenic steroid users? |
| Study acronym | rhGH on performance |
| Study objectives | Short-term recombinant human Growth Hormone (rhGH) administration increases strength, power and endurance performance in healthy, abstinent Anabolic-Androgenic Steroid (AAS) using weight lifters. |
| Ethics approval(s) | University of Glamorgan ethics committee. Originally approved on the 22nd January 2002 (ref: SEC3), amended and final approval was granted on the 20th November 2002 (ref: SEC7). |
| Health condition(s) or problem(s) studied | Anabolic-Androgenic Steroid (AAS) users |
| Intervention | All physiological tests were performed in the same order for both the experimental group and the controls. Subjects were familiarised with testing procedures. Subjects were examined daily over a period of six weeks between the hours of 09:00 and 11:00 and were anonymous to each other. Subjects were administered rhGH, under supervision, by subcutaneous abdominal injection, in a controlled hygienic environment, for six consecutive days in a dosage of 0.058 International Units (IU)/kg/day (0.019 mg/kg/day). Subjects were examined prior to the commencement of rhGH administration (day one), one day after six days administration (day seven), and eight days after cessation (day 14). Dietary intake was strictly monitored, using a fourteen day dietary recall. The control group were an exercise control group and did not take an active substance. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Recombinant human Growth Hormone |
| Primary outcome measure | Increased strength, power and endurance performance indices. |
| Secondary outcome measures | 1. Reduced body fat 2. Increased fat free mass 3. Increased heart rate |
| Overall study start date | 01/08/2004 |
| Completion date | 01/10/2004 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | 48 |
| Key inclusion criteria | Healthy individual weight lifters, who were previous experienced users of AAS, in a 12 week abstinent phase |
| Key exclusion criteria | Positive urinalysis for ergogenic aids |
| Date of first enrolment | 01/08/2004 |
| Date of final enrolment | 01/10/2004 |
Locations
Countries of recruitment
- United Kingdom
- Wales
Study participating centre
University of Glamorgan
1 Lantwit Road
Treforrest
Cardiff
CF37 1DL
United Kingdom
Treforrest
Cardiff
CF37 1DL
United Kingdom
Sponsor information
University of Glamorgan
University/education
University/education
1 Lantwit Road
Treforrest
Cardiff
CF37 1DL
Wales
United Kingdom
| Website | http://www.glam.ac.uk/ |
|---|---|
"ROR" |
https://ror.org/02mzn7s88 |
Funders
Funder type
University/education
University of Glamorgan (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/06/2007 | Yes | No |
Editorial Notes
29/06/2016: Publication reference added
